Case Control Study

Diabetic kidney disease: Are the reported associations with single-nucleotide polymorphisms disease-specific?

Marek Saracyn, Bartłomiej Kisiel, Maria Franaszczyk, Dorota Brodowska-Kania, Wawrzyniec Żmudzki, Robert Malecki, Longin Niemczyk, Przemysław Dyrla, Grzegorz Kamiński, Rafał Płoski, Stanisław Niemczyk

ORCID number: Marek Saracyn 0000-0002-5800-0500; Bartłomiej Kisiel 0000-0001-6311-0475; Maria Franaszczyk 0000-0002-0719-1933; Dorota Brodowska-Kania 0000-0002-3328-1537; Wawrzyniec Żmudzki 0000-0002-1015-456X; Robert Malecki 0000-0003-1217-6395; Longin Niemczyk 0000-0001-9698-9930; Przemysław Dyrla 0000-0002-9546-5614; Grzegorz Kamiński 0000-0002-2357-0634; Rafał Płoski 0000-0001-6286-5526; Stanisław Niemczyk 0000-0001-8151-860X.

Author contributions: Saracyn M, Kisiel B, Płoski R and Niemczyk S designed the study; Saracyn M, Brodowska-Kania D, Żmudzki W, Niemczyk L and Malecki R collected clinical data and blood samples; Franaszczyk M and Saracyn M, isolated DNA; Franaszczyk M and Płoski R genotyped SNP’s; Kisiel B performed statistical analysis; Saracyn M, Kisiel B, Dyrla P, Kamiński G, Płoski R and Niemczyk S interpreted clinical and genetic data; Saracyn M, Kisiel B and Brodowska-Kania D searched literature; Saracyn M, Kisiel B, Płoski R and Niemczyk S prepared the manuscript; all authors contributed to final writing, proof-reading of the manuscript; all authors approved the final version of the paper.

Marek Saracyn, Dorota Brodowska-Kania, Wawrzyniec Żmudzki, Stanisław Niemczyk, Department of Internal Diseases, Nephrology and Dialysis, Military Institute of Medicine, Warsaw 04-141, Poland

Marek Saracyn, Dorota Brodowska-Kania, Grzegorz Kamiński, Department of Endocrinology and Isotope Therapy, Military Institute of Medicine, Warsaw 04-141, Poland

Bartłomiej Kisiel, Clinical Research Support Center, Military Institute of Medicine, Warsaw 04-141, Poland

Maria Franaszczyk, Department of Medical Biology, Molecular Biology Laboratory, Institute of Cardiology, Warsaw 04-628, Poland

Robert Malecki, Department of Nephrology, Międzyleski Specialist Hospital in Warsaw, Warsaw 04-749, Poland

Longin Niemczyk, Department of Nephrology, Dialysis and Internal Diseases, Warsaw Medical University, Warsaw 02-097, Poland

Przemysław Dyrla, Department of Gastroenterology, Military Institute of Medicine, Warsaw 04-141, Poland

Rafał Płoski, Department of Medical Genetics, Medical University of Warsaw, Warsaw 02-106, Poland

Corresponding author: Marek Saracyn, MD, PhD, Associate Professor, Department of Internal Diseases, Nephrology and Dialysis, Military Institute of Medicine, 128 Szaserów Street, Warsaw 04-141, Poland. msaracyn@interia.pl

Abstract

BACKGROUND
The genetic backgrounds of diabetic kidney disease (DKD) and end-stage kidney disease (ESKD) have not been fully elucidated.

AIM
To examine the individual and cumulative effects of single-nucleotide polymorphisms (SNPs) previously associated with DKD on the risk for ESKD of diabetic etiology and to determine if any associations observed were specific for
DKD.

METHODS
Fourteen SNPs were genotyped in hemodialyzed 136 patients with diabetic ESKD (DKD group) and 121 patients with non-diabetic ESKD (NDKD group). Patients were also re-classified on the basis of the primary cause of chronic kidney disease (CKD). The distribution of alleles was compared between diabetic and non-diabetic groups as well as between different sub-phenotypes. The weighted multilocus genetic risk score (GRS) was calculated to estimate the cumulative risk conferred by all SNPs. The GRS distribution was then compared between the DKD and NDKD groups as well as in the groups according to the primary cause of CKD.

RESULTS
One SNP (rs841853; SLC2A1) showed a nominal association with DKD ($P = 0.048; P > 0.05$ after Bonferroni correction). The GRS was higher in the DKD group ($0.615 \pm 0.260$) than in the NDKD group ($0.590 \pm 0.253$), but the difference was not significant ($P = 0.46$). The analysis of associations between GRS and individual factors did not show any significant correlation. However, the GRS was significantly higher in patients with glomerular disease than in those with tubulointerstitial disease ($P = 0.014$) and in those with a combined group (tubulointerstitial, vascular, and cystic and congenital disease) ($P = 0.018$).

CONCLUSION
Our results suggest that selected SNPs that were previously associated with DKD may not be specific for DKD and may confer risk for CKD of different etiology, particularly those affecting renal glomeruli.

Key Words: Diabetic kidney disease; Chronic kidney disease; End-stage kidney disease; Single-nucleotide polymorphism; Diabetes mellitus

Core Tip: The genetic background of diabetic kidney disease (DKD) and end-stage kidney disease (ESKD) has not been fully elucidated. This study on a large population of dialyzed patients shows that single-nucleotide polymorphisms (SNPs) previously described in diabetes mellitus type 2 patients with DKD are not associated with the risk for ESKD of a diabetic background. Instead, the analyzed SNPs seem to correlate with glomerular kidney disease. These findings suggest that chronic kidney disease of different etiologies but the same dominant location of the pathological processes may share a common genetic background.

Citation: Saracyn M, Kistel B, Franaszczuk M, Brodowska-Kania D, Żmudzki W, Malecki R, Niemczyk L, Dyrla P, Kamiński G, Płoski R, Niemczyk S. Diabetic kidney disease: Are the reported associations with single-nucleotide polymorphisms disease-specific? World J Diabetes 2021; 12(10): 1765-1777

URL: https://www.wjgnet.com/1948-9358/full/v12/i10/1765.htm
DOI: https://dx.doi.org/10.4239/wjd.v12.i10.1765

INTRODUCTION
A diabetes mellitus (DM) epidemic is underway; in 2019, approximately 463 million people worldwide were estimated to have DM, and half of those cases were considered undiagnosed. By 2045, the prevalence is expected to increase to 700 million cases[1-3]. In Poland, around 3.5 million people (9.1% of the total population) suffer from DM[4]. Roughly 30% of patients with type 1 DM (DM1) and 40% with type 2 DM (DM2) develop a serious complication of the small renal vessels: diabetic kidney disease (DKD)[5,6]. The occurrence of DKD considerably worsens the long-term prognosis — the risk of premature death in end-stage kidney disease (ESKD) patients
requiring renal replacement therapy (RRT) is 18-fold greater than in the general population[7]. Understandably, DKD is the strongest single predictor of death in a diabetic patient[8]. It is estimated that the number of DKD-associated deaths in DM patients increased by 94% from 1990 to 2012[9]. The recognized risk factors for DKD are hyperglycemia, acute kidney injury, hypertension, and obesity; however, age, gender, race, and family history are also influential factors[10].

Both clinical and epidemiological studies on DKD show a familial association of the disease[11-13], suggesting that heredity plays an important role in its development. Investigators aiming to elucidate the genetic basis of DKD have used two different approaches: candidate gene studies (CGS) and genome-wide association studies (GWAS). During the last two decades, CGS have tested more than 150 loci for their potential relationship with the renal complications of DM[14-16] and have reported an association between several single-nucleotide polymorphisms (SNPs) and albuminuria, glomerular filtration rate (GFR), DKD, and ESKD in both DM1 and DM2 patients. The majority of the proteins encoded by these genes are components of nephron (glomerulus, epithelium, and ion channels), but some are related to the extracellular matrix, immune response, phagocytosis, and cell migration[17]. During the last decade, GWAS have replaced CGS as the study method of choice. The results of GWAS have confirmed some of the CGS findings and have also revealed new associations[18,19]. These initial findings must be corroborated in replication studies in different populations.

With the increasing number of identified genetic risk factors for multifactorial diseases, tools that assess the cumulative impact of these factors on disease risk have been developed. One such tool is the genetic risk score (GRS), which our group has successfully applied in earlier studies[20,21]. GRS is particularly useful in situations wherein the individual effect carried by a single genetic variant is small. Previous studies have shown the capability of GRS to measure the genetic risk of various multifactorial diseases, including myocardial infarction, atrial fibrillation, stroke, rheumatoid arthritis, and psoriasis[22]. Thus, several studies have used this approach to evaluate the risk of renal complications in DM[23-25].

Previous analyses have searched for associations between genetic markers and the risk of diabetic renal complications but may have overlooked a critical issue: whether these genetic markers are specific for DKD or are, rather, associated with the risk for chronic kidney disease (CKD), regardless of its explicit underlying cause.

The aim of our study was to examine the individual and cumulative effects of SNPs previously described in DM2 patients with DKD on the risk for ESKD of diabetic etiology in a population of hemodialyzed (HD) patients and to determine if any associations observed were specific for DKD.

**MATERIALS AND METHODS**

This study was approved by the Military Institute of Medicine Ethics Committee, Warsaw, Poland. Informed consent was obtained from each patient. All procedures were performed in accordance with the Helsinki Declaration of 1975, revised in 1983.

**Patients and controls**

From an initial group of 1246 ESKD/HD patients, 136 consecutive patients with DM2 and DKD as the primary cause of ESKD were included in this study; they formed the DKD group. The control group was composed of 121 age-matched ESKD/HD patients with non-DKD (NDKD); this was the NDKD group. The inclusion criteria were as follows: (1) ESKD treated by hemodialysis; and (2) Age ≥ 18 years. The exclusion criterion was the presence of malignancy. The patients were recruited from the Military Institute of Medicine in Warsaw, Poland, and the Mazovian Centers of Dialysis in the following cities in Poland: Radom, Ciechanów, Grodzisk Mazowiecki, Maków Mazowiecki, Sokółki Podlaski, Sierniewice, Warszawa Międzyzdrzlesie, Wołomin, and Otwroch. Patients were classified as DKD or NDKD on the basis of histopathological examinations and diagnoses made by two independent nephrologists in each of the Mazovian Dialysis Centers. Nineteen DKD patients and 11 NDKD patients were excluded from the study because of poor DNA quality or incomplete genotyping data; the final DKD and NDKD groups consisted of 117 and 110 patients, respectively. Nineteen patients in the NDKD group were classified by nephrologists as having kidney disease of complex pathogenesis (CP group). A structured questionnaire was used to collect data regarding age, gender, smoking habits, body mass index (BMI), history of kidney disease in the pre-ESKD/HD period,
presence and volume of diuresis, and coexistence of hypertension and current treatment. Then, the patients were re-classified on the basis of the 2012 Kidney Disease Improving Global Outcomes (KDIGO) guidelines and CKD classification system based on the primary cause of their kidney disease. These classifications included (1) glomerular disease (GD); (2) tubulointerstitial disease (TID); (3) vascular disease (VD); and (4) cystic and congenital disease (CCD). Patients with CP were considered separately [26].

SNP selection

SNPs previously associated with DKD in DM2 patients were selected for this study [27-38]. The inclusion criteria for SNP selection were as follows: (1) Association with DKD in the presence of DM2 confirmed in a GWAS, meta-analysis, or large-scale case-control study; (2) Odds ratio (OR) ≥ 1.2 (or ≤ 0.83); and (3) Minor allele frequency ≥ 0.1 in a Caucasian population (based on data from the HapMap CEU). The exclusion criteria were as follows: (1) Association limited to non-Caucasian populations; or (2) Lack of studies on Caucasian populations. On the basis of these criteria, 14 SNPs were selected for genotyping. However, five of the genotyped SNPs were excluded from the analysis because of a low genotyping success rate (< 80%) or Hardy-Weinberg equilibrium (HWE) deviation: rs9521445 (MYO16/IRS2), rs1801133 (MTHFR), rs2241766 (ADIPOQ), rs5186 (AGTR1), and rs4880 (SOD2). The complete list of the analyzed SNPs is shown in Supplementary Table 1.

Genotyping

The salting out method was used to isolate DNA form whole blood samples [39]. For SNP genotyping, a custom array was designed (Taqman® OpenArray® Genotyping Plate, Custom Format 16 QuantStudio™ 12 K Flex, Life Technologies, Carlsbad, CA, United States), and genotyping was performed following the manufacturer’s protocols on a QuantStudio™ 12 K Flex Real-Time PCR System (Applied Biosystems, Foster City, CA, United States).

Statistical analysis

The statistical methods used in this study were reviewed by Kisiel B of the Clinical Research Support Center, Military Institute of Medicine, Warsaw, Poland. The differences in allele distribution between cases and controls as well as HWE were evaluated using the PLINK v1.07 statistical software package [40]. The deviation from HWE was considered significant at \( P < 0.05 \). The rest of statistical analyses was undertaken with the use of Statistica 12 package (StatSoft Inc). A Bonferroni correction (\( P \text{ value} \times \text{number of tested SNPs} \) was used to adjust for multiple comparisons. To evaluate the cumulative risk of multiple loci a GRS (computed by summing the products of the number of risk alleles and the natural logarithm of the OR for each SNP) was calculated. For the calculation of GRS we used ORs from previous studies (Supplementary Table 1). The GRSs of the DKD and NDKD groups were compared using Student’s \( t \)-test, whereas the GRSs of GD, VD, TID, CCD, and CP groups were compared using ANOVA. Pearson’s test was used to assess the correlations between different parameters.

RESULTS

The clinical and demographic data of the subjects are presented in Table 1. The DKD and NDKD groups differed significantly with respect to BMI (\( P = 0.01 \)) and treatment with beta-blockers (\( P = 0.015 \)).

SNP associations with DKD are detailed in Table 2. Only one SNP (rs841853) showed a nominal association with DKD (\( P = 0.048; \) \( P > 0.05 \) after Bonferroni correction).

To evaluate the cumulative risk of multiple loci, we calculated GRS; it was slightly higher in the DKD group (0.615 ± 0.260) than in the NDKD group (0.590 ± 0.253), but the difference was not significant (\( P = 0.46 \)). The GRS difference remained not significant (\( P = 0.34 \)) after the exclusion of 19 CP patients from the DKD group: 0.615 ± 0.260 for the DKD group and 0.582 ± 0.244 for the NKD group. The analysis of associations between GRS and the individual factors of gender, diuresis, and rate of CKD progression in the DKD and NDKD groups showed a significant correlation of GRS with diuresis in the NDKD group (0.643 ± 0.22 for diuresis > 500 mL vs 0.535 ± 0.253 for diuresis < 500 mL, \( P = 0.035 \), Table 3).
Table 1 Study and control group characteristics

|                  | DKD (n = 117) | NDKD (n = 110) | P value |
|------------------|---------------|----------------|---------|
| Age (yr)         | 68.94 (7.90)  | 69.87 (10.86)  | 0.46    |
| Male sex (%)     | 57 (48.72)    | 66 (60.00)     | 0.088   |
| Time-to-dialysis (yr) | 5.25 (5.16)  | 6.23 (6.09)    | 0.20    |
| Rapid progression of CKD (TTD ≤ 3 mo) (%) | 6 (5.13) | 6 (5.45) | 0.91 |
| Fast progression of CKD (TTD ≤ 1 yr) (%) | 29 (24.79) | 21 (19.09) | 0.30 |
| Slow progression of CKD (TTD > 5 yr) (%) | 37 (31.62) | 43 (39.09) | 0.24 |
| BMI (kg/m²)      | 30.21 (16.35) | 26.01 (5.15)   | 0.01    |
| Smoking ever (%) | 52 (44.44)    | 58 (53.21)     | 0.19    |
| Preserved diuresis (%) | 97 (82.91) | 85 (77.27) | 0.29 |
| 24 h diuresis > 500 mL (%) | 49 (41.88) | 46 (41.82) | 0.99 |
| Hypertension (%) | 114 (97.44)   | 102 (92.73)    | 0.099   |
| ACE-I (%)        | 50 (43.48)    | 39 (39.39)     | 0.54    |
| ARB (%)          | 17 (14.78)    | 12 (11.76)     | 0.51    |
| Beta-blockers (%)| 89 (76.72)    | 91 (89.22)     | 0.015   |
| Statins (%)      | 76 (66.09)    | 57 (58.16)     | 0.23    |

1Data available for 109 patients.  
2Data available for 115 patients.  
3Data available for 116 patients.  
4Data available for 99 patients.  
5Data available for 102 patients.  
6Data available for 98 patients. 

Significant differences are highlighted in bold. ACE-I: Angiotensin-converting enzyme inhibitors; ARB: Angiotensin II receptor blockers; BMI: Body mass index; CKD: Chronic kidney disease; DKD: Diabetic kidney disease; NDN: Non-diabetic kidney disease; TTD: Time-to-dialysis (time between the diagnosis of chronic kidney disease and start of hemodialysis).

Table 2 Single-nucleotide polymorphisms’ associations with diabetic kidney disease

| SNP              | DKD            | NDKD           | OR       | P value |
|------------------|----------------|----------------|----------|---------|
| rs1617640        | 123            | 111            | 119      | 101     | 0.94 (0.65-1.36) | 0.78 |
| rs841853         | 84             | 150            | 60       | 160     | 1.49 (1.00-2.23) | 0.048 |
| rs18002783       | 67             | 167            | 69       | 151     | 0.88 (0.59-1.31) | 0.53 |
| rs1531343        | 23             | 211            | 17       | 203     | 1.30 (0.68-2.51) | 0.43 |
| rs1800470        | 91             | 143            | 93       | 127     | 0.87 (0.60-1.26) | 0.46 |
| rs759853         | 94             | 140            | 74       | 146     | 1.32 (0.90-1.94) | 0.15 |
| rs1801282        | 40             | 194            | 35       | 185     | 1.06 (0.66-1.79) | 0.73 |
| rs13293564       | 104            | 130            | 91       | 129     | 1.13 (0.78-1.65) | 0.51 |
| rs2268388        | 29             | 205            | 32       | 188     | 0.83 (0.48-1.43) | 0.50 |

DKD: Diabetic kidney disease; E: Effect allele; NDKD: Non-diabetic kidney disease; N: Non-effect allele; OR: Odds ratio; SNP: Single nucleotide polymorphism.

We analyzed the distribution of GRS in the GD, TID, VD, CCD, and CP groups using ANOVA; the differences between groups were not significant (Table 4). However, post hoc analysis showed a significantly higher GRS in the GD group (0.628 ± 0.256) than in the TID group (0.461 ± 0.218) (P = 0.014) as well as a higher GRS in the GD group (0.628 ± 0.256) than in the combined TID+VD+CCD group (0.536 ± 0.235) (P
Table 3: Associations between genetic risk score and different parameters in diabetic kidney disease and non-diabetic kidney disease patients

| Parameter                        | DKD + NDKD, n = 227 | DKD, n = 117 | NDKD, n = 91 |
|----------------------------------|----------------------|--------------|--------------|
|                                  | GRS, mean ± SD       | P value      | GRS, mean ± SD | P value      | GRS, mean ± SD | P value |
| Rapid progression (TTD ≤ 3 mo vs > 3 mo) | 0.602 ± 0.233 vs 0.603 ± 0.258 | 0.99         | 0.518 ± 0.273 vs 0.620 ± 0.260 | 0.34         | 0.687 ± 0.167 vs 0.574 ± 0.246 | 0.27     |
| Fast progression (TTD ≤ 1 yr vs > 1 yr) | 0.592 ± 0.246 vs 0.606 ± 0.260 | 0.75         | 0.600 ± 0.229 vs 0.620 ± 0.270 | 0.71         | 0.522 ± 0.253 vs 0.593 ± 0.242 | 0.30     |
| Slow progression (TTD > 5 yr vs ≤ 5 yr) | 0.596 ± 0.256 vs 0.607 ± 0.258 | 0.77         | 0.629 ± 0.286 vs 0.608 ± 0.249 | 0.69         | 0.583 ± 0.230 vs 0.580 ± 0.257 | 0.96     |
| Diuresis (preserved diuresis vs no diuresis) | 0.614 ± 0.260 vs 0.557 ± 0.239 | 0.18         | 0.622 ± 0.265 vs 0.578 ± 0.235 | 0.49         | 0.605 ± 0.244 vs 0.503 ± 0.235 | 0.09     |
| 24h diuresis > 500 mL (< 500 mL) | 0.630 ± 0.244 vs 0.583 ± 0.265 | 0.17         | 0.621 ± 0.258 vs 0.611 ± 0.263 | 0.83         | 0.643 ± 0.220 vs 0.535 ± 0.253 | 0.035    |
| Male sex (males vs females) | 0.639 ± 0.265 vs 0.591 ± 0.255 | 0.31         | 0.617 ± 0.263 vs 0.586 ± 0.249 | 0.37         | 0.589 ± 0.251 vs 0.568 ± 0.235 | 0.70     |

1Cases with complex pathogenesis excluded from analysis.

DKD: Diabetic kidney disease; NDKD: Non-diabetic kidney disease; GRS: Genetic risk score; TTD: Time-to-dialysis (time between the diagnosis of chronic kidney disease and start of hemodialysis). Significant differences are highlighted in bold.

Table 4: The distribution of genetic risk score in particular end-stage kidney disease subgroups

| Group | GRS | P value | Post-hoc analysis |
|-------|-----|---------|------------------|
|       |     |         | GD vs TID        | P = 0.014 |
|       |     |         | GD vs VD         | P = 0.12  |
|       |     |         | GD vs CCD        | P = 0.61  |
|       |     |         | GD vs CP         | P = 0.97  |
|       |     |         | TID vs VD        | P = 0.24  |
|       |     |         | TID vs CCD       | P = 0.18  |
|       |     |         | TID vs CP        | P = 0.051 |
|       |     |         | VD vs CCD        | P = 0.64  |
|       |     |         | VD vs CP         | P = 0.29  |
|       |     |         | CCD vs CP        | P = 0.66  |

Classification: (1) GD, (2) TID+VD+CCD, (3) CP

| Group | GRS | P value | Post-hoc analysis |
|-------|-----|---------|------------------|
|       |     |         | GD vs TID+VD+CCD | P = 0.018 |
|       |     |         | GD vs CP         | P = 0.97  |
|       |     |         | TID+VD+CCD vs CP | P = 0.16  |

Classification: (1) GD, (2) TID+VD+CCD+CP

| Group | GRS | P value | Post-hoc analysis |
|-------|-----|---------|------------------|
|       |     |         | GD vs CP         | N/A       |
|       |     |         | TID+VD+CCD vs CP | P = 0.16  |

Genetic risk score is presented as mean ± SD. GRS: Genetic risk score; GD: Glomerular disease; TID: Tubulointerstitial disease; VD: Vascular diseases; CCD: Cystic and congenital disease; CP: Complex pathogenesis; N/A: Not applicable.

The analysis of associations between GRS and the individual factors of gender, diuresis, and rate of CKD progression did not show any significant correlation in the GD group (Supplementary Table 2).
DISCUSSION

To the best of our knowledge, this study may be the first to assess the genetic risk of DKD and other nephropathies leading to ESKD and RRT in a relatively large group of HD patients. Unexpectedly, none of the selected SNPs previously described in DM2 patients and associated with DKD development significantly correlated with DKD in our group of ESKD patients requiring hemodialysis, except one (rs841853) that showed a nominal association with DKD ($P = 0.048; P > 0.05$ after Bonferroni correction). Moreover, the GRS composed of all genotyped SNPs, carrying the cumulative risk of all tested loci, did not differ significantly between the DKD and NDKD groups and did not associate with any of the analyzed clinical parameters, including the rate of renal failure progression. This observation may have three explanations: (1) The analyzed SNPs are not associated with DKD in a Polish population; (2) The analyzed SNPs are associated with earlier stages of DKD; or (3) The analyzed SNPs are not specific for DKD but are associated with different kidney diseases and their progression.

It should be emphasized that many earlier studies on the genetic background of DKD have used DM patients without DKD as controls. This approach has identified risk factors for DKD development but has been unable to assess their specificities. That is, the genetic factors that have been pinpointed to be associated with DKD are not necessarily specific for DKD. To address this issue, we re-classified our patients on the basis of the KDIGO guidelines and found that GRS was significantly higher in the CD group than in the TID group and the combined TID+VD+CCD group. This observation suggests that these SNPs that were previously described as associated with DKD are in fact associated with the risk of CKD and ESKD of different etiologies, particularly those primarily affecting renal glomeruli.

In recent years, research has focused on the genetic basis of DKD. Nearly 160 genes have been implicated in DKD development as found in CS5 and GWAS, and there appears to be a multigenic etiology of disease as gauged by GRS[14-19]. In a study involving 1100 DM2 patients, Wang et al[23] demonstrated that a GRS composed of six SNPs in genes involved in lipid metabolism (PON1, PON2, CETP), hemostasis (ITGA2), and inflammation (LTA1, LTA3) was associated with a significantly higher risk of DKD; risks were lower when SNPs were individually assessed. Todd et al[24] examined a GRS composed of 32 validated BMI loci to determine the relationship between BMI and macroalbuminuria, ESKD, and DKD and found that a 1 kg/m2 higher BMI increased the risk of macroalbuminuria by 28%, of ESKD by 43%, and of DKD by 33%. Barbieux et al[25] explored the association between 18 CKD-related SNPs and CKD G5 in 1,300 DM2 patients and 300 DM1 patients; however, neither a single SNP nor the 18-SNP GRS was linked to the deterioration of renal function, need for RRT, or death. Our study cannot be directly compared with the ones referenced above because it followed a completely different, exclusively DKD-related set of SNPs and a dissimilar study design in which non-diabetic patients were used as controls for diabetic ESKD patients.

The main finding of our study is that SNPs reported to be associated with DKD alone may, in fact, be correlated with CKD of different etiology. In this context, two papers are worth mentioning. A large-scale GWAS on 130,000 subjects of European ancestry by Pattaro et al[41] showed that 53 known and novel SNP loci were highly correlated with GFR in individuals with or without diabetes; the effects on both patient groups were of similar magnitude. A study of even larger scale (including over 280,000 subjects from the Million Veteran Program, over 765,000 subjects from the CKD Gen Consortium, and more than 90,000 diabetic patients) published by Hellwege et al[42] made similar observations: 32 SNP loci (17 known and 15 new) were significantly and with similar effect size associated with GFR in both diabetic and non-diabetic groups. Of course, reduced GFR is not synonymous with CKD (or DKD) and ESKD; however, the findings by Pattaro et al[41] and Hellwege et al[42] raise the possibility that CKDs of different etiologies may, to some extent, share a common genetic basis.

To address this issue, we reviewed recent publications regarding the possible relationship of our SNPs with CKD/ESKD of etiology other than DKD[43-50]. Most reports, whether on small or large populations, testing single or many variants, did not include the exact SNPs selected for our study, although they may have involved the same genes. For example, Hellwege et al[42] found an association between GFR and NOS3 (nitric oxide synthase type 3) (rs3918226), but it was a different variation, which showed only a moderate linkage disequilibrium with our NOS3 SNP (rs1800783) ($R^2 = 0.17$)[42]. Similarly, our SNPs were not any of those used in a GWAS by Wuttke et al[43], the largest meta-analysis to date. Essential differences exist between our study and the other studies cited, and simple comparisons are not applicable. First, the aforementioned studies characterized associations between SNPs and GFR in the
general population or in specific subpopulations such as diabetic patients, whereas our study aimed to delineate relationships between the selected SNPs and ESKD. Undoubtedly, changes in GFR are not synonymous with ESKD. In fact, a GWAS by Lin et al. [44] indicated that the majority of loci do not overlap between early stages of CKD and ESKD, suggesting that distinct genetic factors may dominate at different stages of CKD. Second, a GWAS detects only the strongest associations, as corrections for a number of analyses are routinely used, possibly neglecting more nuanced but still meaningful effects on outcome measures. Third, studies on the general population, which include patients with CKDs of different etiologies, may simply not pick up disease-specific associations due to a water-downed subject pool. The association of the SNPs selected for our study with CKDs of different etiologies, and not only DKD, is supported by the fact that their corresponding loci carry information affecting the structure and function of nephrons or interstitial renal tissue, the disorders of which are not restricted to diabetic etiology. In fact, the most common causes of CKD, such as DKD, hypertensive nephropathy, atherosclerotic nephropathy, renal mass reduction, obstructive nephropathy, and glomerular diseases, share many common pathophysiological pathways [45]. The factor initiating kidney injury is clearly different, but the progression of renal damage may involve mutual mechanisms, such as the renin-angiotensin-aldosterone system; endothelial, podocyte, mesangial, and tubular cell activation; platelet activation; common cytokine activation pathways (transforming growth factor-β1); the spread of inflammation; and repair of damaged tissues (fibrosis). A shared pathophysiology is even more probable in diseases affecting the same region of the kidney — in this case, the renal glomeruli. This study has several strengths. First, the study group included only patients with ESKD, which addresses the suggestion made by earlier research that different CKD stages may be driven by distinctive genetic factors. Second, non-diabetic ESKD patients comprised our control group; this allowed us to answer the question whether the SNPs previously associated with DKD are specific for that type of CKD; indeed, we demonstrated that the SNPs in question were not specific for ESKD of diabetic etiology. We must also acknowledge the major limitation of this study: its size. The study group was relatively small for a genetic analysis. However, owing to our strict inclusion criteria, the initial population of approximately 1200 patients with ESKD requiring RRT from dialysis centers in Mazovia, Poland, which has a general population of about 5.5 million, was winnowed down to those patients with documented DKD as the primary cause of ESKD and an appropriate, non-DKD control group with ESKD of etiology other than diabetes. Due to relatively small study group our results need to be confirmed in studies on larger populations.

CONCLUSION

Our study may be the first to demonstrate that selected SNPs that were previously associated with DKD may not be specific for DKD and may confer genetic risk for CKDs of different etiologies, particularly those affecting renal glomeruli. Our results need to be confirmed in studies on larger populations.

ARTICLE HIGHLIGHTS

Research background

A diabetes mellitus (DM) epidemic is underway; 40% patients with type 2 DM (DM2) develop a serious complication, diabetic kidney disease (DKD), and the occurrence of DKD considerably worsens the long-term prognosis. However, the genetic backgrounds of DKD and end-stage kidney disease (ESKD) have not been fully elucidated.

Research motivation

Previous studies have searched for associations between genetic markers and the risk of diabetic renal complications but may have overlooked a critical issue: whether these genetic markers are specific for DKD or are, rather, associated with the risk for chronic kidney disease and ESKD itself, regardless of its explicit underlying cause.
Research objectives
The aim of our study was to examine the individual and cumulative effects (as a genetic risk score, GRS) of SNPs previously described in DM2 patients with DKD on the risk of diabetic ESKD in a population of hemodialyzed patients and to determine if any associations observed were specific for DKD.

Research methods
Fourteen SNPs were genotyped in 136 patients with diabetic ESKD (DKD group) and 121 patients with non-diabetic ESKD (NDKD group). Patients were also classified on the basis of the KDIGO guidelines and CKD classification system based on the primary cause of CKD, such as glomerular disease (GD), tubulointerstitial disease (TID), vascular disease (VD), and cystic and congenital disease (CCD). Patients with complex pathogenesis (CP) were considered separately. The distribution of alleles was compared between diabetic and non-diabetic groups as well as between different sub-phenotypes. The weighted multilocus GRS was calculated to estimate the cumulative risk conferred by all SNPs. The distribution of GRS was then compared between the DKD and NDKD groups as well as in the groups according to KDIGO guidelines.

Research results
One SNP (rs841853; SLC2A1) showed a nominal association with DKD ($P = 0.048$; $P > 0.05$ after Bonferroni correction). The GRS was higher in the DKD group ($0.615 \pm 0.260$) than in the NDKD group ($0.590 \pm 0.253$), but the difference was not significant ($P = 0.46$). The analysis of associations between GRS and the individual factors of gender, diuresis, and rate of CKD progression in either study group did not show any significant correlation. However, the GRS was significantly higher in the GD group than in the TID group ($P = 0.014$) and the combined TID+VD+CCD group ($P = 0.018$).

Research conclusions
Our study may be the first to demonstrate that selected SNPs that were previously associated with DKD may not be specific for DKD and may confer genetic risk for CKDs of different etiologies, particularly those affecting renal glomeruli.

Research perspectives
Further studies are needed to confirm a similar correlation of other SNPs previously associated with DKD with the development and etiology of ESKD.

ACKNOWLEDGEMENTS
We thank all medical staff members and technicians of dialysis centers who agreed to participate in this study.

REFERENCES

1. Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. *Clin J Am Soc Nephrol* 2017; 12: 2032-2045 [PMID: 28522654 DOI: 10.2215/CJN.11491116]
2. Piccoli GB, Grassi G, Caibiddu G, Nazha M, Roggero S, Capizzi I, De Pascale A, Priola AM, Di Vico C, Maxia S, Loi V, Asmus AM, Pani A, Veltri A. Diabetic Kidney Disease: A Syndrome Rather Than a Single Disease. *Rev Diabet Stud* 2015; 12: 87-109 [PMID: 26676663 DOI: 10.1900/RDS.2015.12.87]
3. Saeddi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, Shaw JE, Bright D, Williams R; IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. *Diabetes Res Clin Pract* 2019; 157: 107843 [PMID: 31518657 DOI: 10.1016/j.diabres.2019.107843]
4. Niklas A, Marcinkowska J, Kozeła M, Pajak A, Zdrojewski T, Drygas W, Piwnicka A, Kwaśniewska M, Kożakiewicz K, Tykarska A. Blood pressure and cholesterol control in patients with hypertension and hypercholesterolemia: the results from the Polish multicenter national health survey WOBASZ II. *Pol Arch Intern Med* 2019; 129: 864-873 [PMID: 31596271 DOI: 10.20452/pamw.15013]
5. United States Renal Data System. Annual Data Report: Epidemiology of Kidney Disease in the United States, Bethesda, MD, National Institute of Diabetes and Digestive and Kidney Diseases, 2015. [cited 14 March 2021]. In: United States Renal Data System [Internet]. Available from: https://www.usrds.org/annual-data-report/
6. Reutens AT. Epidemiology of diabetic kidney disease. *Med Clin North Am* 2013; 97: 1-18 [PMID:
Saracyn M et al. Value of SNPs in DKD

23290726 DOI: 10.1016/j.mena.2012.10.001

7 Group PH, Thomas MC, Moran JL, Wådén J, Thorn LM, Mäkinen VP, Rosengård-Bärlund M, Sarafheimo M, Hietala K, Heikkilä O, Forsslom C; FinnDiame Study Group. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 2009; 58: 1651-1658 [PMID: 19401416 DOI: 10.2337/db08-1543]

8 Dousampanis P, Trigka K, Mouzaki A. Tregs and kidney: From diabetic nephropathy to renal transplantation. World J Transplant 2016; 6: 556-563 [PMID: 27663634 DOI: 10.5500/wjt.v6.i3.556]

9 Jha V, García-García G, Iseki K, Li Z, Naïcier S, Plattert B, Saraan R, Wang AY, Yang WY. Chronic kidney disease: global dimension and perspectives. Lancet 2013; 382: 260-272 [PMID: 23727169 DOI: 10.1016/S0140-6736(13)60687-X]

10 Taal MW. Risk factors and chronic kidney disease. In: Skorecki K, Brenner and Rector’s The Kidney, 10th ed. Amsterdam, Elsevier, 2015: 669-692

11 Freedman BI, Boostrom M, DaeiHagh P, Bowden DW. Genetic factors in diabetic nephropathy. Clin J Am Soc Nephrol 2007; 2: 1306-1316 [PMID: 17942768 DOI: 10.2215/CJN.02560607]

12 Sandholm N, Group PH. Genetic basis of diabetic kidney disease and other diabetic complications. Curr Opin Genet Dev 2018; 50: 17-24 [PMID: 29453109 DOI: 10.1016/j.gde.2018.01.002]

13 Guo J, Rackham OJL, Sandholm N, He B, Østerholm AM, Valo E, Harjutsalo V, Forsblom C, Toppila I, Parkkonen M, Li Q, Zhu W, Harmston N, Chothani S, Ohman MK, Eng E, Sun Y, Petretto E, Group PH, Tryggvason K. Whole-Genome Sequencing of Finnish Type 1 Diabetic Siblings Discordant for Kidney Disease Reveals DNA Variants Associated with Diabetic Nephropathy. J Am Soc Nephrol 2020; 31: 309-323 [PMID: 31919106 DOI: 10.1681 ASN.2019030289]

14 Hanson RL, Craig DW, Millis MP, Yeatts KA, Kovesis AE, Pearlson GW, Kretzler M, Kato Y, Yamaoka Y, Collins AJ, Groop PH. The association between 38 previously reported polymorphisms and the relevance of disease duration. Diabetes 2013; 62: 3273-3284 [PMID: 24120300 DOI: 10.2337/db12-0765]

15 Maeda S, Ishikawa Y, Kurashige M, Araki S, Suzuki D, Babazono T, Uzu T, Umezono T, Toyoda M, Kawai K, Imanishi M, Hanaoka K, Maegawa H, Uchigata Y, Hasegawa K. Replication study for the association of 3 SNP loci identified in a genome-wide association study for diabetic nephropathy in European type 1 diabetes with diabetic nephropathy in Japanese patients with type 2 diabetes. Clin Exp Nephrol 2013; 17: 866-871 [PMID: 23543049 DOI: 10.1007/s10292-012-0139-8]

16 Sandholm N, Salem RM, McKnight AJ, Brennan EP, Forsblom C, Isakova T, McKay GJ, Williams WW, Sadlier DM, Mäkinen VP, Swan EJ, Palmer C, Boright AG, Ahlyquist E, Deshmukh HA, Keller BJ, Huang H, Ahola A, Fagerholm E, Gordin D, Harjutsalo V, He B, Heikkilä O, Hietala K, Kytö J, Lahermo P, Lehto M, Lithovius R, Østerholm AM, Parkkonen M, Pitkäniemi J, Rosengård-Bärlund M, Sarafheimo M, Sarti C, Soderlund J, Trempus PS, Luo X, Molina-Ramos M, Mäkinen VP, Sipponen M, Soderlund J, Tuomilehto J. Genetic and Epigenetic Studies in Diabetic Kidney Disease. Curr Opin Genet Dev 2016; 38: 10-16

17 Gu HF. Genetic and Epigenetic Studies in Diabetic Kidney Disease. Front Genet 2019; 10: 507 [PMID: 31231424 DOI: 10.3389/fgene.2019.00507]

18 Nicholas A, Fatima S, Lamari A, Bellili-Muñoz N, Halimi JM, Saulnier PJ, Hadjadj S, Velho G, Marre M, Roussel R, Fumeron F. ABCG8 polymorphisms and renal disease in type 2 diabetic patients. Metabolism 2015; 64: 713-719 [PMID: 25804128 DOI: 10.1016/j.metabol.2015.03.005]

19 Sandholm N, Haukka JK, Toppila I, Valo E, Harjutsalo V, Forsblom C, Group PH. Confirmation of GLRA3 as a susceptibility locus for albuminuria in Finnish patients with type 1 diabetes. Sci Rep 2018; 8: 12408 [PMID: 30120300 DOI: 10.1038/s41598-018-29211-1]

20 Saracyn M, Kisiel B, Bacht A, Franaszczuk M, Brodowska-Kania D, Zmudzki W, Zmyszko S, Kolaski A, Klatko W, Stopiński M, Grochowski J, Papiłski M, Goździk Z, Niemczyk L, Bober B, Kolodziej M, Tustochowicz W, Kamiński G, Ploski R, Niemczyk S. Value of multicollinear genetic risk score for atrial fibrillation in end-stage kidney disease patients in a Polish population. Sci Rep 2018; 8: 9284 [PMID: 29915175 DOI: 10.1038/s41598-018-27382-5]

21 Kisiel B, Kisiel K, Szymański K, Mackiewicz W, Biało-Wójcicka E, Uczniak S, Fogtman A, Iwasicka-Nowicka R, Kobliowska M, Kossovska H, Placha G, Sykułski M, Bacht A, Tustochowicz W, Ploski R, Kaszuba A. The association between 38 previously reported polymorphisms and psoriasis in a Polish population: High predicative accuracy of a genetic risk score combining 16 Loci. PLoS One 2017; 12: e0179348 [PMID: 28617847 DOI: 10.1371/journal.pone.0179348]

22 Kisiel B, Kraszewski R, Juszczakiewicz A, Marciniak A, Klos K, Duda K, Maliborski A, Szymański K, Ploski R, Saracyn M, Niemczyk S, Kisiel K, Tustochowicz M, Tustochowicz W. Common atherosclerosis genetic risk factors and subclinical atherosclerosis in rheumatoid arthritis: the relevance of disease duration. Rheumatol Int 2019; 39: 327-336 [PMID: 30374689 DOI: 10.1007/s00296-018-4186-y]

23 Wang Y, Luk AO, Ma RC, So WY, Tam CH, Ng MC, Yang X, Lam V, Tong PC, Chan JC. Predictive role of multicollinear genetic polymorphisms in cardiovascular disease and inflammation-
related genes on chronic kidney disease in Type 2 diabetes—an 8-year prospective cohort analysis of 1163 patients. *Nephrol Dial Transplant* 2012; 27: 190-196 [PMID: 21765051 DOI: 10.1093/ndt/gfr343]

24 Todd JN, Dahlström EH, Salem RM, Sandholm N, Forsblom C, FinnDiane Study Group, McKnight AJ, Maxwell AP, Brennan E, Sadlier D, Godson C, Groop PH, Hirschhorn JN, Flores JC. Genetic Evidence for a Causal Role of Obesity in Diabetic Kidney Disease. *Diabetes* 2015; 64: 4238-4246 [PMID: 26307587 DOI: 10.2337/db15-0254]

25 Barbier P, György B, Gand E, Saunier PJ, Ducroq G, Halimi JM, Feigerlova E, Hulin-Delmonte C, Latty P, Montaigne D, Rigalleau V, Roussel R, Rosner P, Zouapi P, Ragot S, Marre M, Tregouët DA, Hadjadj S; SURDIAGENE Study Group, French JDRF Diabetic Nephropathy Collaborative Research Initiative (Search for genes determining time to onset of ESRD in T1D patients with proteinuria). No prognostic role of a GWAS-derived genetic risk score in renal outcomes for patients from French cohorts with type 1 and type 2 diabetes. *Diabetes Metab* 2019; 45: 494-497 [PMID: 29540294 DOI: 10.1016/j.diabet.2018.01.016]

26 Kidney International Supplements. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Int* 2013; 3: 1-150

27 Nazir N, Siddiqui K, Al-Qasim S, Al-Naqeb D. Meta-analysis of diabetic nephropathy associated genetic variants in inflammation and angiogenesis involved in different biochemical pathways. *BMC Med Genet* 2014; 15: 103 [PMID: 25280384 DOI: 10.1186/s12881-014-0103-8]

28 Pezzolesi MG, Poznik GD, Skupien J, Smiles AM, Mychaleckyj JC, Rich SS, Warram JH, Krelovska AS. An intergenic region on chromosome 13q33.3 is associated with the susceptibility to kidney disease in type 1 and 2 diabetes. *Kidney Int* 2011; 80: 105-111 [PMID: 21412220 DOI: 10.1038/ki.2010.64]

29 McKnight AJ, Patterson CC, Sandholm N, Kilner J, Buckham TA, Parkkonen M, Forsblom C, Sadlier DM, Groop PH, Maxwell AP, Warren 3/UK GoKinD Study Group. Genetic polymorphisms in nitric oxide synthase 3 gene and implications for kidney disease: a meta-analysis. *Am J Nephrol* 2010; 32: 476-481 [PMID: 20962522 DOI: 10.1159/000302240]

30 Alkaysyali S, Lajer M, Deshmukh H, Alkhvost E, Colhouan H, Isomaa B, Rossing P, Groop L, Lyssenko V. Common variant in the HMGA2 gene increases susceptibility to nephropathy in patients with type 2 diabetes. *Diabetologia* 2013; 56: 323-329 [PMID: 23111731 DOI: 10.1007/s00125-012-2760-5]

31 Jia H, Yu L, Gao B, Ji Q. Association between the T869C polymorphism of transforming growth factor-beta 1 and diabetic nephropathy: a meta-analysis. *Endocrine* 2011; 40: 372-378 [PMID: 21725704 DOI: 10.1007/s12020-011-9503-0]

32 Moovaart AL, Valk EJ, van Es LA, Bruijn JA, de Heer E, Freedman BI, Dekkers OM, Baelde HJ. Genetic associations in diabetic nephropathy: a meta-analysis. *Diabetologia* 2011; 54: 544-553 [PMID: 21127830 DOI: 10.1007/s00125-010-1996-1]

33 Li T, Shi Y, Yin J, Qin Q, Wei S, Nie S, Liu L. The association between lipid metabolism gene polymorphisms and nephropathy in type 2 diabetes: a meta-analysis. *Int J Nephrol* 2015; 47: 117-130 [PMID: 25262149 DOI: 10.1155/2015/122555 DOI: 10.1159/000321340]

34 Zhou TB, Drummen GP, Jiang ZP, Li HY. Methylenetetrahydrofolate reductase (MTHFR) C677T gene polymorphism and diabetic nephropathy susceptibility in patients with type 2 diabetes. *Diabetologia* 2013; 56: 323-329 [PMID: 23111731 DOI: 10.1007/s00125-012-2760-5]

35 Cui W, Du B, Zhou W, Jia Y, Sun G, Sun J, Zhang D, Yuan H, Xu F, Lu X, Luo P, Miao L. Relationship between five GLUT1 gene single nucleotide polymorphisms and diabetic nephropathy: a systematic review and meta-analysis. *Mol Biol Rep* 2012; 39: 8551-8558 [PMID: 22707195 DOI: 10.1007/s11033-012-1711-z]

36 Cai Y, Zeng T, Chen L. Association of adiponectin polymorphisms with the risk of diabetic nephropathy in type 2 diabetes: a meta-analysis. *J Diabetes* 2015; 7: 31-40 [PMID: 24825737 DOI: 10.1111/1753-0407.12166]

37 Ding W, Wang F, Fang Q, Zhang M, Chen J, Gu Y. Association between two genetic polymorphisms of the renin-angiotensin-aldosterone system and diabetic nephropathy: a meta-analysis. *Mol Biol Rep* 2012; 39: 1293-1303 [PMID: 21607620 DOI: 10.1007/s10075-011-0662-7]

38 Tian C, Fang S, Du X, Jia C. Association of the C47T polymorphism in SOD2 with diabetes mellitus and diabetic microvascular complications: a meta-analysis. *Diabetologia* 2011; 54: 803-811 [PMID: 21218397 DOI: 10.1007/s00125-010-2004-5]

39 Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic Acids Res* 1988; 16: 1215 [PMID: 3344216 DOI: 10.1093/na/16.12.1215]

40 Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC. Value of SNPs in DKD

41 Pattaro C, Teumer A, Gorski M, Chu AY, Li M, Majtovic V, Garnaa M, Tin A, Sorice R, Li Y, Talun D, Olden M, Foster M, Yang Q, Chen MH, Pers TH, Johnson AD, Ko YA, Fuchsberger C, Tayo B, Nallis M, Feitosa MF, Isaacs A, Dehghan A, d’Adamo P, Adeyemo A, Diefenbach AK, Zonderman AB, Nolte IM, van der Most PJ, Wright AF, Shuldiner AR, Morrison AC, Hofman A, Smith AV, Dreisbach AW, Franke A, Uitterlinden AG, Metspalu A, Tonjes A, Lupo A, Robino A, Johansson A, Demirkan A, Kollieris B, Freedman BI, Ponte B, Oostra BA, Paulweber B, Krämer BK, Mitchell BD, Buckley BM, Peralta CA, Hayward C, Helmer C, Rotimi CN, Shaffer CM, Müller C, Sala C, van Duijn CM, Saint-Pierre A, Ackermann D, Shriner D, Ruggiero D, Toniolo D, Lu Y, Cusi
Saracyn M et al. Value of SNPs in DKD

D, Czamara D, Ellingshaus D, Siscovick DS, Ruderfer D, Gieger C, Grallert H, Roehchchina E, Atkinson JH, Holliday EG, Boerwinkle E, Salvi E, Bottinger EP, Murgia F, Rivadeneira F, Ernst F, Kronenberg F, Hu FB, Navis GJ, Curhan GC, Ehret GB, Hormuth G, Coassin S, Thun GA, Gieger C, Gambaro G, Malerba G, Montgomery GW, Eiriksdottir G, Jacobs G, Li W, Wichmann HE, Campbell H, Schmidt H, Wallaschofski H, Völzke H, Brenner H, Kroemer HK, Kramer H, Lin H, Leach IM, Ford I, Guessous I, Rudan I, Prokopenko I, Borecki I, Heid IM, Kolcic I, Persico I, Jukema JW, Wilson JF, Felix JF, Divers J, Lamia, Paul JD, Wang JJ, Ding I, Hirschhorn JN, Attia J, Whitley JB, Chalmers J, Viikari J, Denny IC, Karjalainen J, Fernandes JK, Endlich K, Batterback K, Keene KL, Lohman K, Portas L, Launer LJ, Lyytiäkäinen LP, Vengo I, Franke L, Ferrucci L, Rose LM, Kedeno L, Rao M, Struchalin M, Kleber ME, Cavaieri M, Haun M, Cornelis MC, Cuijol M, Pirastu M, de Andrade M, McEvoy MA, Woodward M, Adam M, Coca C, Nauck M, Imboden M, Waldenberger M, Pruit M, Metzger M, Stunzov M, Evans MK, Sale MM; ACHIEVE consortium; CHARGE-Heart Failure Group; ECHlogen Consortium, Kovacs P, Wild PS, Froguel P, Rettig R, Mägi R, Biffar R, Schmidt R, Middelberg RP, Carroll RJ, Penninx BW, Scott RJ, Katz R, Sedaghat S, Wild SH, Kardia S, Uli S, Hvsgewa SJ, Enroth S, Klobier S, Trumpet S, Stengel B, Hancock SJ, Turner ST, Rosas SE, Stracke S, Harris TB, Zeller T, Zemunek M, Lehtimäki T, Illig T, Aspensd T, Nokkensipust T, EKso T, Tanaka T, Gyllensten U, Völker U, Emilsson V, Vittar V, Aalto V, Guadnson V, Chouraki V, Chen WM, IgI W, März W, Koenig V, Lieb W, Loos RA, Li V, Yenneyliser H, Pramstaller PP, Susztak K, Hamet P, Tremblay J, de Boer HJ, Böger CA, Goessling W, Chassan DM, Kötgen A, Kao WH, Fox CS. Genetic associations at 53 Loci highlight cell types and biological pathways relevant for kidney function. Nat Commun 2016; 7: 10023 [PMID: 26831199 DOI: 10.1038/ncomms10023]
Wilson JG, Dehghan A, Parsa A, Chasman DI, Ho K, Morris AP, Devuyst O, Akilesh S, Pendergrass SA, Sim X, Böger CA, Okada Y, Edwards TL, Snieder H, Stefansson K, Hung AM, Heid IM, Scholz M, Teumer A, Köttgen A, Pattaro C. A catalog of genetic loci associated with kidney function from analyses of a million individuals. \textit{Nat Genet} 2019; 51: 957-972 [PMID: 31152163 DOI: 10.1038/s41588-019-0407-x]

Lin BM, Nadkarni GN, Tao R, Graff M, Fornage M, Buyske S, Matise TC, Highland HM, Wilkens LR, Carlson CS, Park SL, Seriawan VW, Ambite JL, Heiss G, Boerwinkle E, Lin DY, Morris AP, Loos RJF, Kooperberg C, North KE, Wassel CL, Franceschini N. Genetics of Chronic Kidney Disease Stages Across Ancestries: The PAGE Study. \textit{Front Genet} 2019; 10: 494 [PMID: 31178898 DOI: 10.3389/fgene.2019.00494]

López-Novoa JM, Martínez-Salgado C, Rodríguez-Peña AB, López-Hernández FJ. Common pathophysiological mechanisms of chronic kidney disease: therapeutic perspectives. \textit{Pharmacol Ther} 2010; 128: 61-81 [PMID: 20600306 DOI: 10.1016/j.pharmthera.2010.05.006]

Morris AP, Le TH, Wu H, Akbarov A, van der Most PJ, Hernandi G, Smith GD, Mahajan A, Gaulton KJ, Nadkarni GN, Valladares-Salgado A, Wacher-Rodarte N, Mychaleckyj JC, Duiker ND, Guo X, Hai Y, Haessler J, Kamatani Y, Stilp AM, Zhu G, Cook JP, Ārnlov J, Blanton SH, de Borst MH, Bottinger EP, Buchanan TA, Cechova S, Charchar FJ, Chu PL, Damman J, Eales J, Gharavi AG, Giedraitis V, Heath AC, Ipp E, Kryluk K, Kramer HJ, Kubo M, Larsson A, Lindgren CM, Lu Y, Madden PAF, Montgomery GW, Papanicolaou GJ, Raffel LJ, Sacco RL, Sanchez E, Stark H, Sundstrom J, Taylor KD, Xiang AH, Zivkovic A, Lind L, Ingelsson E, Martin NG, Whitfield JB, Cai J, Laurie CC, Okada Y, Matsuda K, Kooperberg C, Chen YI, Rundek T, Rich SS, Loos RJF, Parra EJ, Cruz M, Rotter JJ, Snieder H, Tomaszewski M, Humphreys BD, Franceschini N. Trans-ethnic kidney function association study reveals putative causal genes and effects on kidney-specific disease aetiologies. \textit{Nat Commun} 2019; 10: 29 [PMID: 30604766 DOI: 10.1038/s41467-018-07867-7]

Salem RM, Todd JN, Sandholm N, Cole JB, Chen WM, Andrews D, Pezzolesi MG, McKean-Peipme PM, Hiraki LT, Qui C, Nair V, Di Liao C, Cao JJ, Valo E, Onengut-Gumuscu S, Smiles AM, McGuraghan SJ, Haukka JK, Harjutsalo V, Brennan EP, van Zuydam N, Ahlqvist E, Doyle R, Ahluwalia TS, Lajer M, Hughes MF, Park J, Skupien J, Spiliopoulou A, Liu A, Menon R, Boustany-Kari CM, Kang HM, Nelson RG, Klein R, Klein BE, Lee KE, Gao X, Mauker M, Maestroni S, Caramori ML, de Boer IH, Miller RG, Guo J, Boright AP, Tregouet D, Gyorgy B, Snell-Bergeon JK, Maas DM, Bull SB, Canty AJ, Palmer CNA, Stechemesser L, Paulweber B, Weitgasser R, Sokolovskaja V, Rovito P, Pirìa E, Prakapieni E, Radzевичи E, Verkausi Ki L, Panduru NM, Groop LC, MCCarthy MI, Gu HF, Möllsten A, Falhammar H, Brismar K, Martin F, Rossing P, Costacou T, Florczak JC, SUMMIT Consortium, DCCT/EDIC Research Group, GENIE Consortium. Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology Involved in Glomerular Basement Membrane Collagen. \textit{J Am Soc Nephrol} 2019; 30: 2000-2016 [PMID: 31537649 DOI: 10.1681/ASN.2019030218]

Cyprus C, Chathoth S, Vatte C, Alrubaisa N, Almuhamma O, Borgio JP, Al-Mueilo S, Al Muhamma F, Al Ali AK. Novel Haplotype Indicator for End-Stage Renal Disease Progression among Saudi Patients. \textit{Int J Nephrol} 2019; 2019: 1095215 [PMID: 31534799 DOI: 10.1155/2019/1095215]

Thomson RJ, McMorran B, Hoy W, Jose M, Whittcock L, Thornton T, Burgio G, Mathews JD, Foote S. New Genetic Loci Associated With Chronic Kidney Disease in an Indigenous Australian Population. \textit{Front Genet} 2019; 10: 330 [PMID: 31040861 DOI: 10.3389/fgene.2019.00330]

Gast C, Marinaki A, Arenas-Hernandez M, Campbell S, Seaby EG, Pengelly RJ, Gale DP, Connor TM, Bunyan DJ, Hodafová K, Živná M, Knoch S, Ennis S, Venkat-Raman G. Autosomal dominant tubulointerstitial kidney disease-UOMD is the most frequent non polygenic genetic kidney disease. \textit{BMC Nephrol} 2018; 19: 301 [PMID: 30376835 DOI: 10.1186/s12882-018-1107-y]
